Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$44.16 USD

44.16
820,650

-1.02 (-2.26%)

Updated Mar 30, 2023 04:00 PM ET

After-Market: $44.14 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.52%
2Buy18.26%
3Hold9.60%
4Sell5.38%
5Strong Sell2.61%
S&P50010.68%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for CRSP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 1,815 2,379 1,690 944 457
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 38 38 26 44 10
Total Current Assets 1,853 2,418 1,717 988 466
Net Property & Equipment 164 138 42 31 19
Investments & Advances 53 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 16 22 18 6 4
Total Assets 2,243 2,752 1,828 1,067 489
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 27 15 9 6 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 78 92 64 31 21
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 10 12 1
Total Current Liabilities 121 120 94 57 28
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 0 12 12 58
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6 20 8 14 11
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 368 352 164 127 97
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 2 2
Capital Surplus 2,735 2,598 2,236 1,162 682
Retained Earnings -846 -196 -574 -225 -292
Other Equity -16 -5 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,875 2,399 1,664 939 392
Total Liabilities & Shareholder's Equity 2,243 2,752 1,828 1,067 489
Total Common Equity 1,875 2,399 1,664 939 392
Shares Outstanding 78.20 76.50 71.20 55.20 51.90
Book Value Per Share 23.98 31.37 23.37 17.02 7.56

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Assets          
Cash & Equivalents 1,815 1,896 2,065 2,221 2,379
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 38 37 42 39 38
Total Current Assets 1,853 1,933 2,107 2,261 2,418
Net Property & Equipment 164 166 165 157 138
Investments & Advances 53 77 8 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 16 16 16 16 22
Total Assets 2,243 2,353 2,463 2,606 2,752
Liabilities & Shareholders Equity 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Notes Payable 0 0 0 0 0
Accounts Payable 27 32 25 27 15
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 78 107 86 75 92
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 1
Total Current Liabilities 121 151 120 114 120
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 12 12 12 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6 6 7 20
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 368 399 373 361 352
Shareholders Equity 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 2 2
Capital Surplus 2,735 2,709 2,670 2,635 2,598
Retained Earnings -846 -736 -561 -375 -196
Other Equity -16 -22 -20 -17 -5
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,875 1,954 2,091 2,245 2,399
Total Liabilities & Shareholder's Equity 2,243 2,353 2,463 2,606 2,752
Total Common Equity 1,875 1,954 2,091 2,245 2,399
Shares Outstanding 78.20 78.20 77.40 77.40 76.50
Book Value Per Share 23.98 24.99 27.01 29.00 31.37